Premium
Serum osteoprotegerin levels and long‐term prognosis in subjects with stable coronary artery disease
Author(s) -
JONO S.,
OTSUKI S.,
HIGASHIKUNI Y.,
SHIOI A.,
MORI K.,
HARA K.,
HASHIMOTO H.,
IKARI Y.
Publication year - 2010
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2010.03833.x
Subject(s) - osteoprotegerin , medicine , coronary artery disease , proportional hazards model , cardiology , prospective cohort study , gastroenterology , receptor , activator (genetics)
Summary. Background: Osteoprotegerin (OPG) is a secretory glycoprotein which belongs to the tumor necrosis factor receptor family. OPG immunoreactivity was demonstrated in normal blood vessels and in early atherosclerotic lesions. In a previous study, we showed that high serum OPG levels are associated with progression of coronary artery disease (CAD). Objectives: The present study was designed to assess the association between serum OPG level and long‐term prognosis in patients with stable coronary artery disease. Methods: We performed a prospective, observational cohort study in 225 subjects to examine whether serum OPG levels can predict cardiovascular mortality. The median OPG levels were 1.02 ng mL −1 at baseline. Results : During the follow‐up (61 ± 25 months), 27 deaths occurred including 13 cardiovascular deaths. When the subjects were divided into three groups according to serum OPG level, the group with high serum OPG showed a higher risk for cardiovascular mortality. A Multivariate Cox proportional hazards model indicated that the higher risk of cardiovascular death in the high OPG level group remained significant (hazards ratio of 7.44, 95%CI 0.92–60.30, highest vs. lowest OPG tertile). In contrast, serum OPG levels were not associated with non‐cardiovascular mortality. Conclusions: Our data show that serum OPG levels are an independent predictor of cardiovascular mortality in patients with stable coronary artery disease.